Accueil Ernstrade Bourse Actualite Stock



BerGenBio AS is a clinical stage biopharmaceutical company focused on developing first-in-class drugs for aggressive cancers. The company is a world leader in understanding the biology of epithelial-mesenchymal transition (EMT), a widely recognised key pathway in immune evasion, acquired cancer drug-resistance and metastasis. BerGenBio AS is founded on proprietary platform technology, CellSelect™, to identify and validate novel drug targets and biomarkers. The company has progressed its lead drug candidate BGB324, an EMT inhibitor, into clinical trials in AML and NSCLC, while pursuing the pre-clinical development of additional compounds and proprietary EMT drug targets.

BerGenBio Secures NOK212 Million Capital Raise
BERGEN, Norway, March 18, 2016 /PRNewswire/ --

BerGenBio AS ("BerGenBio" or the "Company") has announced that it has secured a capital raise of NOK212 million (c. $25 million) in a private placement from existing shareholders, including Investinor AS and Meteva AS.

Copyright  2016